MetaCap

Celcuity (CELC) vs Lumexa Imaging (LMRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celcuity is the larger company by market cap ($2.61 billion vs $1.37 billion), about 1.9 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELC-47.06%LMRI-23.00%
+49%-10%-69%
Dec 11, 20251 yearNov 20, 2026
CELC-49.31%LMRI-23.04%
+36%-15%-67%
Dec 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELC versus LMRI key metrics
MetricCELCLMRI
Share price$53.35$14.26
Market cap$2.61B$1.37B
1-day change-5.26%+1.42%
YTD return-46.51%-22.92%
1-year return-45.28%—
5-year return+249.61%—
Forward P/E—15.18
EPS (TTM)$-4.72$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-177.04M—
52-week high$151.02$19.45
52-week low$53.20$6.45
Distance from 52-week high-64.67%-26.68%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+182.76%+31.70%
Average volume1.25M372.45K
Shares outstanding48.93M96.12M
Employees1555,000
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Celcuity

CELC stock →

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).

Health Care · Medical Specialities · 155 employees

About Lumexa Imaging

LMRI stock →

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States.

Health Care · Medical Specialities · 5,000 employees

CELC vs LMRI FAQ

Which is bigger, Celcuity or Lumexa Imaging?

Celcuity (CELC) is larger, with a market capitalization of $2.61B compared with $1.37B for Lumexa Imaging (LMRI).

Are Celcuity and Lumexa Imaging in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons